Progress of Targeted Therapy and Immunotherapy for Gastric Cancer
10.3971/j.issn.1000-8578.2024.23.1257
- VernacularTitle:胃癌靶向及免疫治疗进展
- Author:
Yu ZHENG
1
;
Hongming PAN
Author Information
1. Department of Oncology, Sir Run Run Shaw Hospital College of Medicine, Zhejiang University, Hangzhou 310063, China
- Publication Type:Research Article
- Keywords:
Gastric cancer;
Targeted therapy;
Immunotherapy
- From:
Cancer Research on Prevention and Treatment
2024;51(4):234-239
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer (GC) is a common malignant tumor of the digestive tract in China. It is characterized by high morbidity, mortality, and proportion of patients in advanced stages. In the past years, chemotherapy was used as the main treatment for GC. Subsequently, targeted therapy with trastuzumab was approved to treat HER2-positive GC. However, the progress of drug development and clinical studies has been limited by the high heterogeneity of GC. In recent years, research on immunotherapy and new targets for therapeutic exploration in GC has made great strides. Herein, we provide a brief review of the progress of the research on targeted therapy and immunotherapy for GC.
